Sorafenib in patients with hepatocellular carcinoma: results of the observational INSIGHT study
Purpose: Sorafenib is the only currently approved systemic therapy for advanced hepatocellular carcinoma (HCC). We aimed to evaluate the safety and efficacy of sorafenib therapy in patients with HCC under real-life conditions regarding patient, tumor characteristics, and any adverse events at study...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 2017
|
| In: |
Clinical cancer research
Year: 2017, Jahrgang: 23, Heft: 19, Pages: 5720-5728 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-16-0919 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1158/1078-0432.CCR-16-0919 Verlag, Volltext: http://clincancerres.aacrjournals.org/content/23/19/5720 
|
| Verfasserangaben: | Tom M. Ganten, Rudolf E. Stauber, Eckardt Schott, Peter Malfertheiner, Robert Buder, Peter R. Galle, Thomas Göhler, Matthias Walther, Ronald Koschny, and Guido Gerken |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576400883 | ||
| 003 | DE-627 | ||
| 005 | 20220814164221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180615s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-16-0919 |2 doi | |
| 035 | |a (DE-627)1576400883 | ||
| 035 | |a (DE-576)506400883 | ||
| 035 | |a (DE-599)BSZ506400883 | ||
| 035 | |a (OCoLC)1341011533 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ganten, Tom M. |d 1969- |e VerfasserIn |0 (DE-588)115539670 |0 (DE-627)69139010X |0 (DE-576)289938899 |4 aut | |
| 245 | 1 | 0 | |a Sorafenib in patients with hepatocellular carcinoma |b results of the observational INSIGHT study |c Tom M. Ganten, Rudolf E. Stauber, Eckardt Schott, Peter Malfertheiner, Robert Buder, Peter R. Galle, Thomas Göhler, Matthias Walther, Ronald Koschny, and Guido Gerken |
| 264 | 1 | |c October 2017 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.06.2018 | ||
| 520 | |a Purpose: Sorafenib is the only currently approved systemic therapy for advanced hepatocellular carcinoma (HCC). We aimed to evaluate the safety and efficacy of sorafenib therapy in patients with HCC under real-life conditions regarding patient, tumor characteristics, and any adverse events at study entry and at follow-up visits every 2 to 4 months. Experimental Design: The current INSIGHT study is a noninterventional, prospective, multicenter, observational study performed in 124 sites across Austria and Germany between 2008 and 2014. Results: Median overall survival and time to progression (RECIST) were found to be dependent on baseline Barcelona Clinic Liver Cancer (BCLC) tumor stage (A: 29.2, B: 19.6, C: 13.6, D: 3.1 and A: 6.0, B: 5.5, C: 3.9, and D: 1.7 months, respectively), Child-Pugh liver function (A: 17.6, B: 8.1, C: 5.6 and A: 5.3, B: 3.3, C: 2.5 months, respectively), and performance status of the patient; however, age did not affect prognosis. Sorafenib-related adverse events at any grade occurred in 64.9% of patients, with diarrhea (35.4%), hand-foot-skin reaction (16.6%), nausea (10.3%), and fatigue (11.2%) occurring most frequently. Conclusions: Sorafenib treatment was shown to be effective in a real-life setting, in agreement with previously reported clinical trial data. The therapy was found to have an acceptable safety profile, with predominantly mild to moderate side effects. Clin Cancer Res; 23(19); 5720-8. ©2017 AACR. | ||
| 700 | 1 | |a Koschny, Ronald |d 1974- |e VerfasserIn |0 (DE-588)124377483 |0 (DE-627)70661836X |0 (DE-576)185833950 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 23(2017), 19, Seite 5720-5728 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a Sorafenib in patients with hepatocellular carcinoma results of the observational INSIGHT study |
| 773 | 1 | 8 | |g volume:23 |g year:2017 |g number:19 |g pages:5720-5728 |g extent:9 |a Sorafenib in patients with hepatocellular carcinoma results of the observational INSIGHT study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-16-0919 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://clincancerres.aacrjournals.org/content/23/19/5720 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180615 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 124377483 |a Koschny, Ronald |m 124377483:Koschny, Ronald |d 910000 |d 910100 |e 910000PK124377483 |e 910100PK124377483 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 115539670 |a Ganten, Tom M. |m 115539670:Ganten, Tom M. |d 50000 |e 50000PG115539670 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1576400883 |e 3012735151 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Sorafenib in patients with hepatocellular carcinoma","subtitle":"results of the observational INSIGHT study","title_sort":"Sorafenib in patients with hepatocellular carcinoma"}],"person":[{"role":"aut","family":"Ganten","display":"Ganten, Tom M.","given":"Tom M."},{"given":"Ronald","family":"Koschny","display":"Koschny, Ronald","role":"aut"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"part":{"extent":"9","year":"2017","issue":"19","volume":"23","text":"23(2017), 19, Seite 5720-5728","pages":"5720-5728"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"origin":[{"dateIssuedDisp":"1995-","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995","publisher":"AACR"}],"pubHistory":["1.1995 -"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"recId":"325489971","name":{"displayForm":["American Association for Cancer Research"]},"disp":"Sorafenib in patients with hepatocellular carcinoma results of the observational INSIGHT studyClinical cancer research","language":["eng"],"corporate":[{"display":"American Association for Cancer Research","role":"isb"}],"id":{"eki":["325489971"],"zdb":["2036787-9"],"issn":["1557-3265"]},"type":{"bibl":"periodical","media":"Online-Ressource"}}],"origin":[{"dateIssuedDisp":"October 2017","dateIssuedKey":"2017"}],"language":["eng"],"id":{"doi":["10.1158/1078-0432.CCR-16-0919"],"eki":["1576400883"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Tom M. Ganten, Rudolf E. Stauber, Eckardt Schott, Peter Malfertheiner, Robert Buder, Peter R. Galle, Thomas Göhler, Matthias Walther, Ronald Koschny, and Guido Gerken"]},"note":["Gesehen am 15.06.2018"],"recId":"1576400883"} | ||
| SRT | |a GANTENTOMMSORAFENIBI2017 | ||